NEMAURA MEDICAL INC. (OTCMKTS:NMRD) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0
NEMAURA MEDICAL INC. (OTCMKTS:NMRD) Files An 8-K Regulation FD Disclosure

NEMAURA MEDICAL INC. (OTCMKTS:NMRD) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

On July 7, 2020, Nemaura Medical Inc. (the “Company”) issued a press release announcing the submission of a PMA Application for sugarBEAT® to the U.S. Food and Drug Administration. The press release also announced that Dr. Faz Chowdhury, the Company’s CEO, will be participating in an investor webinar, hosted by RedChip Companies, on Tuesday, July 7, 2020 at 11:00 a.m. ET. A live Q&A session with Dr. Chowdhury will follow the presentation. During the presentation, Dr. Chowdhury will provide an update on the Company’s developments, including commercialization progress, U.S. product launch, and status of collaborative partnerships, as well as update on a continuous temperature monitor (CTM) for both the diabetes and non-diabetes markets. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth under this Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Nemaura Medical Inc. Exhibit
EX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1       Nemaura Medical Submits PMA Application for sugarBEAT® to U.S. FDA Company to Participate in RedChip Webinar on Tuesday,…
To view the full exhibit click here

About NEMAURA MEDICAL INC. (OTCMKTS:NMRD)

Nemaura Medical, Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices. The Company’s focus is on the development of a continuous glucose monitoring (CGM) device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a CGM, named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm.